Clinical Trial Update: The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study [Phase 4]

View source ↗

Summary

Phase 4 trial investigating ambrisentan in combination with spironolactone for pulmonary arterial hypertension has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)
• Spironolactone (spironolactone)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: TERMINATED | Results posted: 2019-11-15